Literature DB >> 27941243

Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Anjie Zhen, Valerie Rezek, Cindy Youn, Brianna Lam, Nelson Chang, Jonathan Rick, Mayra Carrillo, Heather Martin, Saro Kasparian, Philip Syed, Nicholas Rice, David G Brooks, Scott G Kitchen.   

Abstract

Chronic immune activation, immunosuppression, and T cell exhaustion are hallmarks of HIV infection, yet the mechanisms driving these processes are unclear. Chronic activation can be a driving force in immune exhaustion, and type I interferons (IFN-I) are emerging as critical components underlying ongoing activation in HIV infection. Here, we have tested the effect of blocking IFN-I signaling on T cell responses and virus replication in a murine model of chronic HIV infection. Using HIV-infected humanized mice, we demonstrated that in vivo blockade of IFN-I signaling during chronic HIV infection diminished HIV-driven immune activation, decreased T cell exhaustion marker expression, restored HIV-specific CD8 T cell function, and led to decreased viral replication. Antiretroviral therapy (ART) in combination with IFN-I blockade accelerated viral suppression, further decreased viral loads, and reduced the persistently infected HIV reservoir compared with ART treatment alone. Our data suggest that blocking IFN-I signaling in conjunction with ART treatment can restore immune function and may reduce viral reservoirs during chronic HIV infection, providing validation for IFN-I blockade as a potential therapy for HIV infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27941243      PMCID: PMC5199686          DOI: 10.1172/JCI89488

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

4.  Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Authors:  Caroline Goujon; Michael H Malim
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

7.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

8.  Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Authors:  Livio Azzoni; Andrea S Foulkes; Emmanouil Papasavvas; Angela M Mexas; Kenneth M Lynn; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Ian Frank; Michael P Busch; Steven G Deeks; Mary Carrington; Una O'Doherty; Jay Kostman; Luis J Montaner
Journal:  J Infect Dis       Date:  2012-10-26       Impact factor: 5.226

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

View more
  95 in total

1.  HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Authors:  Rebecca T Veenhuis; Zachary T Freeman; Jack Korleski; Laura K Cohen; Guido Massaccesi; Alessandra Tomasi; Austin W Boesch; Margaret E Ackerman; Joseph B Margolick; Joel N Blankson; Michael A Chattergoon; Andrea L Cox
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

Review 2.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.

Authors:  Franck J Barrat; Lishan Su
Journal:  J Exp Med       Date:  2019-08-16       Impact factor: 14.307

3.  Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8+ T Cells.

Authors:  Abena K R Kwaa; Chloe A G Talana; Joel N Blankson
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 4.  Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Authors:  Sabelo Lukhele; Giselle M Boukhaled; David G Brooks
Journal:  Semin Immunol       Date:  2019-05-30       Impact factor: 11.130

5.  Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection.

Authors:  Liang Cheng; Haisheng Yu; Guangming Li; Feng Li; Jianping Ma; Jingyun Li; Liqun Chi; Liguo Zhang; Lishan Su
Journal:  JCI Insight       Date:  2017-06-15

Review 6.  HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Authors:  Sho Sugawara; David L Thomas; Ashwin Balagopal
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-15       Impact factor: 2.205

Review 7.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

Review 8.  Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice.

Authors:  Lishan Su
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

Review 9.  Animal Models for the Study of Nucleic Acid Immunity: Novel Tools and New Perspectives.

Authors:  Isabelle K Vila; Maxence Fretaud; Dimitrios Vlachakis; Nadine Laguette; Christelle Langevin
Journal:  J Mol Biol       Date:  2020-08-26       Impact factor: 5.469

10.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.